London · Delayed Price · Currency is GBP · Price in GBX Dr. Martens Statistics
Total Valuation
Dr. Martens has a market cap or net worth of GBP 686.23 million. The enterprise value is 899.43 million.
| Market Cap | 686.23M |
| Enterprise Value | 899.43M |
Important Dates
The next estimated earnings date is Thursday, August 20, 2026.
| Earnings Date | Aug 20, 2026 |
| Ex-Dividend Date | Aug 27, 2026 |
Share Statistics
Dr. Martens has 957.09 million shares outstanding. The number of shares has increased by 0.57% in one year.
| Current Share Class | 957.09M |
| Shares Outstanding | 957.09M |
| Shares Change (YoY) | +0.57% |
| Shares Change (QoQ) | -4.08% |
| Owned by Insiders (%) | 1.04% |
| Owned by Institutions (%) | 54.88% |
| Float | 510.60M |
Valuation Ratios
The trailing PE ratio is 29.88 and the forward PE ratio is 14.06. Dr. Martens's PEG ratio is 0.59.
| PE Ratio | 29.88 |
| Forward PE | 14.06 |
| PS Ratio | 0.90 |
| PB Ratio | 1.90 |
| P/TBV Ratio | 7.53 |
| P/FCF Ratio | 5.14 |
| P/OCF Ratio | 4.81 |
| PEG Ratio | 0.59 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.69, with an EV/FCF ratio of 6.74.
| EV / Earnings | 37.79 |
| EV / Sales | 1.18 |
| EV / EBITDA | 6.69 |
| EV / EBIT | 12.42 |
| EV / FCF | 6.74 |
Financial Position
The company has a current ratio of 2.61, with a Debt / Equity ratio of 1.09.
| Current Ratio | 2.61 |
| Quick Ratio | 1.56 |
| Debt / Equity | 1.09 |
| Debt / EBITDA | 2.93 |
| Debt / FCF | 2.95 |
| Interest Coverage | 2.61 |
Financial Efficiency
Return on equity (ROE) is 6.54% and return on invested capital (ROIC) is 9.17%.
| Return on Equity (ROE) | 6.54% |
| Return on Assets (ROA) | 5.12% |
| Return on Invested Capital (ROIC) | 9.17% |
| Return on Capital Employed (ROCE) | 10.09% |
| Weighted Average Cost of Capital (WACC) | 5.45% |
| Revenue Per Employee | 321,792 |
| Profits Per Employee | 10,013 |
| Employee Count | 2,377 |
| Asset Turnover | 0.87 |
| Inventory Turnover | 1.49 |
Taxes
In the past 12 months, Dr. Martens has paid 8.90 million in taxes.
| Income Tax | 8.90M |
| Effective Tax Rate | 27.22% |
Stock Price Statistics
The stock price has decreased by -4.02% in the last 52 weeks. The beta is 0.25, so Dr. Martens's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | -4.02% |
| 50-Day Moving Average | 68.23 |
| 200-Day Moving Average | 74.94 |
| Relative Strength Index (RSI) | 54.51 |
| Average Volume (20 Days) | 1,351,287 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Dr. Martens had revenue of GBP 764.90 million and earned 23.80 million in profits. Earnings per share was 0.02.
| Revenue | 764.90M |
| Gross Profit | 506.00M |
| Operating Income | 72.40M |
| Pretax Income | 32.70M |
| Net Income | 23.80M |
| EBITDA | 85.70M |
| EBIT | 72.40M |
| Earnings Per Share (EPS) | 0.02 |
Balance Sheet
The company has 180.30 million in cash and 393.50 million in debt, with a net cash position of -213.20 million or -0.22 per share.
| Cash & Cash Equivalents | 180.30M |
| Total Debt | 393.50M |
| Net Cash | -213.20M |
| Net Cash Per Share | -0.22 |
| Equity (Book Value) | 361.50M |
| Book Value Per Share | 0.38 |
| Working Capital | 257.20M |
Cash Flow
In the last 12 months, operating cash flow was 142.70 million and capital expenditures -9.20 million, giving a free cash flow of 133.50 million.
| Operating Cash Flow | 142.70M |
| Capital Expenditures | -9.20M |
| Depreciation & Amortization | 13.30M |
| Net Borrowing | -49.30M |
| Free Cash Flow | 133.50M |
| FCF Per Share | 0.14 |
Margins
Gross margin is 66.15%, with operating and profit margins of 9.47% and 3.11%.
| Gross Margin | 66.15% |
| Operating Margin | 9.47% |
| Pretax Margin | 4.28% |
| Profit Margin | 3.11% |
| EBITDA Margin | 11.20% |
| EBIT Margin | 9.47% |
| FCF Margin | 17.45% |
Dividends & Yields
This stock pays an annual dividend of 0.03, which amounts to a dividend yield of 3.54%.
| Dividend Per Share | 0.03 |
| Dividend Yield | 3.54% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 103.36% |
| Buyback Yield | -0.57% |
| Shareholder Yield | 2.98% |
| Earnings Yield | 3.47% |
| FCF Yield | 19.45% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Dr. Martens is 100.17, which is 39.71% higher than the current price. The consensus rating is "Buy".
| Price Target | 100.17 |
| Price Target Difference | 39.71% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 4.06% |
| EPS Growth Forecast (3Y) | 20.54% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Dr. Martens has an Altman Z-Score of 5.14 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.14 |
| Piotroski F-Score | 6 |